Vinorelbine
- Generic Name
- Vinorelbine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C45H54N4O8
- CAS Number
- 71486-22-1
- Unique Ingredient Identifier
- Q6C979R91Y
- Background
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .
...
- Indication
Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs .
Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents .
...
- Associated Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Recurrent Cervical Cancer, Soft Tissue Sarcoma
- Associated Therapies
- -
G-Step: Gemcitabine Based Small-cell Lung Cancer Treatment in Elderly Patients
- Conditions
- First Posted Date
- 2006-11-20
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 85
- Registration Number
- NCT00401609
- Locations
- 🇮🇹
Ospedale San Martino, Genova, GE, Italy
🇮🇹Divisione di Oncologia Medica, U.S.L.L. 13, Noale, VE, Italy
🇮🇹Ospedale Umberto di Frosinone, Frosinone, FR, Italy
Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease
- Conditions
- Interventions
- First Posted Date
- 2006-10-16
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 146
- Registration Number
- NCT00388349
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy
- Conditions
- Interventions
- First Posted Date
- 2006-07-06
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Thoraxklinik-Heidelberg gGmbH
- Target Recruit Count
- 132
- Registration Number
- NCT00349089
- Locations
- 🇩🇪
Klinikum Bremen-Ost, Bremen, Germany
🇩🇪Westdeutsches Tumorzentrum, Essen, Germany
🇧🇪Ziekenhuis Oost Limburg, Genk, Belgium
The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-06-27
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 84
- Registration Number
- NCT00345059
- Locations
- 🇮🇹
Ospedali Riuniti, Foggia, FG, Italy
🇮🇹Ospedale Civile di Legnano, Legnano, MI, Italy
🇮🇹Ospedale S. Paolo, Milano, MI, Italy
Phase II Iressa + Irradiation Followed by Chemo in NSCLC
- Conditions
- First Posted Date
- 2006-06-05
- Last Posted Date
- 2007-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 50
- Registration Number
- NCT00333294
- Locations
- 🇫🇷
Research Site, Nantes, France
🇫🇷Research SIte, Paris, France
Pemetrexed-Carboplatin and Gemcitabine-Vinorelbine in Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-05-12
- Last Posted Date
- 2011-05-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 135
- Registration Number
- NCT00325234
- Locations
- 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kayseri, Turkey
Oral Vinorelbine and Cisplatin and Concurrent Radiotherapy After Induction Chemotherapy in Locally Advanced NSCLC.
- Conditions
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2009-07-28
- Lead Sponsor
- University Hospital, Brest
- Target Recruit Count
- 60
- Registration Number
- NCT00295672
- Locations
- 🇫🇷
CHU Hôpital Nord, Saint Etienne, France
🇫🇷Hopital de la Croix Rousse, Lyon, France
🇫🇷CHU de LIMOGES, Limoges, France
Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma
- Conditions
- First Posted Date
- 2006-01-24
- Last Posted Date
- 2016-01-15
- Lead Sponsor
- Bayside Health
- Target Recruit Count
- 12
- Registration Number
- NCT00280878
- Locations
- 🇦🇺
Frankston Hospital, Melbourne, Victoria, Australia
🇦🇺The Alfred Hospital, Melbourne, Victoria, Australia
Phase I-II Study of Carboplatin, Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer
- First Posted Date
- 2006-01-13
- Last Posted Date
- 2010-01-07
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 33
- Registration Number
- NCT00277069
- Locations
- 🇺🇸
University of New Mexico, Albuquerque, New Mexico, United States
Phase II Iressa Versus Vinorelbine (INVITE)
- Conditions
- First Posted Date
- 2005-11-22
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 192
- Registration Number
- NCT00256711
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.